Market Eyes LiveCRISPR Therapeutics AG (CRSP) Stock Rating & Analysis
MELANY's data-driven read on CRISPR Therapeutics AG · Biological Products, (No Diagnostic Substances).
Crispr Therapeutics is a gene-editing company developing therapeutics based on Crispr/Cas9, a technology (clustered regularly interspaced short palindromic repeats and Crispr-associated protein 9) for precisely altering specific genomic DNA sequences. The company applies this technology to genetically defined diseases. Its first approved drug, Casgevy, was developed with Vertex Pharmaceuticals and treats sickle-cell disease and transfusion-dependent beta-thalassemia.
Why CRSP scores 62/100
MELANY scores CRISPR Therapeutics AG 62/100 by weighing eight factors. Here is how CRSP breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- Price +10.8% above 50-day MA
History of beating or missing estimates, and where estimates are heading.
What Wall Street price targets and revisions are signalling.
- Analyst targets 51% upside
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for CRSP
- Operating margin -1128%, cash-burn business, dependent on capital markets
- Negative free cash flow, company consuming cash, not generating it
- Short interest 22% of float, high volatility risk on news
- Performance partly driven by Biotech (GLP-1 + innovation cluster), rotation away from this theme would hurt
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
CRISPR Therapeutics AG sits in the Biotech (GLP-1 + innovation cluster) theme, which MELANY currently rates 80/100 for strength. Theme strength feeds CRSP's momentum and catalyst factors above.
CRSP trade plan (members only)
MELANY has a full position plan for CRISPR Therapeutics AG: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates CRSP
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. CRISPR Therapeutics AG's 62/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about CRSP
Is CRISPR Therapeutics AG (CRSP) a buy?
As of 2026-08-19, MELANY rated CRISPR Therapeutics AG Promising with a composite score of 62/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is CRISPR Therapeutics AG's MELANY score?
CRISPR Therapeutics AG (CRSP) has a MELANY composite score of 62/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the CRSP stock rating calculated?
MELANY scores CRSP from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy CRISPR Therapeutics AG stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates CRISPR Therapeutics AG (CRSP) Promising with a composite of 62/100 as of 2026-08-19. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the CRSP stock price forecast?
MELANY does not publish price targets or forecasts for CRSP. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 62/100 across eight factors for CRISPR Therapeutics AG, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is CRSP stock overvalued or undervalued?
MELANY's valuation factor currently reads 62/100 for CRISPR Therapeutics AG, where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives CRSP's read.
What price should I buy CRSP at?
Rather than chasing the current price, MELANY computes a smart entry zone for CRSP: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying CRSP stock?
The top risks MELANY currently flags for CRISPR Therapeutics AG: Operating margin -1128%, cash-burn business, dependent on capital markets; Negative free cash flow, company consuming cash, not generating it; Short interest 22% of float, high volatility risk on news; Performance partly driven by Biotech (GLP-1 + innovation cluster), rotation away from this theme would hurt; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is CRISPR Therapeutics AG a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 21/100 for CRISPR Therapeutics AG, and earnings track record, at 64/100. The 62/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will CRSP stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 64/100 for CRSP right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this CRSP rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-19. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores CRSP continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
CRSP's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.